Catalytic Intermolecular Asymmetric [2π+2σ] Cycloadditions of Bicyclo[1.1.0]butanes: Practical Synthesis of Enantioenriched Highly Substituted Bicyclo[2.1.1]hexanes

被引:20
作者
Li, Ying-Jie [1 ]
Wu, Zhi-Long [1 ]
Gu, Qiang-Shuai [2 ,3 ]
Fan, Tingting [4 ]
Duan, Ming-Hao [1 ]
Wu, Lihong [1 ]
Wang, Yu-Tao [1 ]
Wu, Ji-Peng [1 ]
Fu, Fang-Lei [1 ]
Sang, Fan [4 ]
Peng, Ai-Ting [1 ]
Jiang, Yuyang [1 ,4 ]
Liu, Xin-Yuan [2 ,3 ]
Lin, Jin-Shun [1 ]
机构
[1] Inst Biopharmaceut & Hlth Engn, Tsinghua Shenzhen Int Grad Sch, State Key Lab Chem Oncogen, Shenzhen 518055, Peoples R China
[2] Southern Univ Sci & Technol, Shenzhen Grubbs Inst, Dept Chem, Shenzhen 518055, Peoples R China
[3] Southern Univ Sci & Technol, Guangming Adv Res Inst, Shenzhen 518055, Peoples R China
[4] Inst Biomed Hlth Technol & Engn, Shenzhen Bay Lab, Shenzhen 518132, Peoples R China
关键词
ENANTIOSELECTIVE SYNTHESIS; COMPLEXITY; PATHWAY;
D O I
10.1021/jacs.4c10968
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
The high percentage of sp3-hybridized carbons and the presence of chiral carbon centers could contribute to increased molecular complexity, enhancing the likelihood of clinical success of drug candidates. Three-dimensional (3D) bridged motifs have recently garnered significant interest in medicinal chemistry. Bicyclo[2.1.1]hexanes (BCHs) are emerging 3D benzene bioisosteres, but the synthesis of chiral, highly substituted BCHs has been underexplored. Herein, we disclose the Lewis acid-catalyzed asymmetric intermolecular [2 pi + 2 sigma] cycloaddition of bicyclo[1.1.0]butanes with coumarins, 2-pyrone, or chromenes to access diverse enantioenriched 1,2,3,4-tetrasubstituted BCHs bearing vicinal tertiary-quaternary stereocenters. The key to success is the introduction of chiral bisoxazoline ligands to effectively suppress the side reactions, inhibit significant racemic background reactions, and fine-tune the reactivity and regio-, enantio-, and diastereoselectivities of the reactions. The resulting BCHs hold significant potential as benzene bioisosteres in the synthesis of chiral BCHex-Sonidegib and BCHex-BMS-202, mimicking the anticancer drug Sonidegib and the PD-1/PD-L1 inhibitor BMS-202, respectively. The outcome highlights the positive impact of bioisosteric replacement on physicochemical properties, while maintaining comparable antitumor activity to their aryl-containing counterparts.
引用
收藏
页码:34427 / 34441
页数:15
相关论文
共 90 条
[21]   Enantioselective [2π+2σ] Cycloadditions of Bicyclo[1.1.0]butanes with Vinylazaarenes through Asymmetric Photoredox Catalysis [J].
Fu, Qianqian ;
Cao, Shanshan ;
Wang, Jiahao ;
Lv, Xinxin ;
Wang, Hao ;
Zhao, Xiaowei ;
Jiang, Zhiyong .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2024, 146 (12) :8372-8380
[22]   Strain-release amination [J].
Gianatassio, Ryan ;
Lopchuk, Justin M. ;
Wang, Jie ;
Pan, Chung-Mao ;
Malins, Lara R. ;
Prieto, Liher ;
Brandt, Thomas A. ;
Collins, Michael R. ;
Gallego, Gary M. ;
Sach, Neal W. ;
Spangler, Jillian E. ;
Zhu, Huichin ;
Zhu, Jinjiang ;
Baran, Phil S. .
SCIENCE, 2016, 351 (6270) :241-246
[23]   Bicyclobutanes as unusual building blocks for complexity generation in organic synthesis [J].
Golfmann, Maxim ;
Walker, Johannes C. L. .
COMMUNICATIONS CHEMISTRY, 2023, 6 (01)
[24]   Copper(I)-Catalyzed Asymmetric Reactions Involving Radicals [J].
Gu, Qiang-Shuai ;
Li, Zhong-Liang ;
Liu, Xin-Yuan .
ACCOUNTS OF CHEMICAL RESEARCH, 2020, 53 (01) :170-181
[25]   Lewis acid-catalyzed diastereoselective carbofunctionalization of bicyclobutanes employing naphthols [J].
Guin, Avishek ;
Bhattacharjee, Subrata ;
Harariya, Mahesh Singh ;
Biju, Akkattu T. .
CHEMICAL SCIENCE, 2023, 14 (24) :6585-6591
[26]   Strain-Release [2π+2σ] Cycloadditions for the Synthesis of Bicyclo[2.1.1]hexanes Initiated by Energy Transfer [J].
Guo, Renyu ;
Chang, Yu-Che ;
Herter, Loic ;
Salome, Christophe ;
Braley, Sarah E. ;
Fessard, Thomas C. ;
Brown, M. Kevin .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2022, 144 (18) :7988-7994
[27]   Small-Molecule Inhibitors of the Programmed Cell Death-1/Programmed Death-Ligand 1 (PD-1/PD-L1) Interaction via Transiently Induced Protein States and Dimerization of PD-L1 [J].
Guzik, Katarzyna ;
Zak, Krzysztof M. ;
Grudnik, Przemyslaw ;
Magiera, Katarzyna ;
Musielak, Bogdan ;
Torner, Ricarda ;
Skalniak, Lukasz ;
Domling, Alexander ;
Dubin, Grzegorz ;
Holak, Tad A. .
JOURNAL OF MEDICINAL CHEMISTRY, 2017, 60 (13) :5857-5867
[28]   Prognostic value of PD-L1 expression in patients with pancreatic cancer A PRISMA-compliant meta-analysis [J].
Hu, Ying ;
Chen, Wanzhen ;
Yan, Zhanpeng ;
Ma, Jingxia ;
Zhu, Fangshi ;
Huo, Jiege .
MEDICINE, 2019, 98 (03)
[29]   Sonidegib: mechanism of action, pharmacology, and clinical utility for advanced basal cell carcinomas [J].
Jain, Sachin ;
Song, Ruolan ;
Xie, Jingwu .
ONCOTARGETS AND THERAPY, 2017, 10 :1645-1653
[30]   Osimertinib (AZD9291) decreases programmed death ligand-1 in EGFR-mutated non-small cell lung cancer cells [J].
Jiang, Xiao-Ming ;
Xu, Yu-Lian ;
Huang, Mu-Yang ;
Zhang, Le-Le ;
Su, Min-Xia ;
Chen, Xiuping ;
Lu, Jin-Jian .
ACTA PHARMACOLOGICA SINICA, 2017, 38 (11) :1512-1520